Blood Screening Market To Reach USD 6.33 Billion By 2031, Growing At 8.50% CAGR | Skyquest Technology

(MENAFN- GetNews)


"Blood Screening Market"Global Blood Screening market size was valued at USD 3.30 Billion in 2023 to USD 6.33 Billion by 2031, at a CAGR of 8.50% during the forecast period (2024-2031).

Global
Blood Screening Market
size was valued at USD 3.04 Billion in 2022 and is poised to grow from USD 3.30 Billion in 2023 to USD 6.33 Billion by 2031, at a CAGR of 8.50% during the forecast period (2024-2031).

The market is driven by increasing incidence of
the diseases
such as HIV, syphilis, syphilis, hemophilia, cancer and other blood related diseases. Serology tests detect the presence of specific antibodies. These tests detect various infectious diseases, including HIV, hepatitis, and syphilis. Molecular tests detect the presence of DNA or RNA from a particular pathogen. Cytology measures the number of certain substances in the blood. This test can detect a variety of
the diseases, including diabetes, kidney disease and liver disease.

Get a Free Sample Research Report:

Blood Screening Market Segmental Analysis

Global Blood Screening Market is segmented based on product type, technology, end users, and region.

Based on product & service , the market is segmented into Reagents & Kits [NAT Reagents & Kits, ELISA Reagents & Kits, Other Reagents & Kits], Instruments [Rental Purchase, Outright Purchase], Software & Services.

Based on technology , the market is segmented into Nucleic Acid Test (NAT) [Transcription-mediated Amplification (TMA), Real-time Polymerase Chain Reaction (RT-PCR)], Serology/Immunoassay [Chemiluminescent Immunoassays (CLIA), Fluorescent Immunoassays (FIA), Colorimetric Immunoassays/ELISA (CI/ELISA)], Rapid Tests, Western Blot Assays, Next-generation Sequencing (NGS).

Based on end user , the market is segmented into hospitals & clinics, diagnostic centres, and blood banks.

Based on region , the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Future Impact in the Next 4-5 Years Accelerated Growth through Technological Advancements

These innovations are expected to drive significant growth in the blood screening market over the next 4-5 years due to the use of advanced testing technologies such as nucleic acid testing (NAT), the next generation sequencing (NGS), and AI-based diagnostics. Detection of
the infectious
diseases, genetic diseases and chronic diseases will be facilitated, improving the accuracy and speed of blood testing protocols. Furthermore, healthcare growing awareness and government policies to ensure safe blood transfusions will further expand the market. However, challenges such as the high cost of advanced technology and regulatory barriers can hinder immediate growth in some areas.

Ask for Customization:

This report covers the following players:

• Abbott Laboratories (USA)
  
• Becton, Dickinson and Company (USA)
  
• Bio-Rad Laboratories, Inc. (USA)
  
• bioMérieux SA (France)
  
• F. Hoffmann-La Roche Ltd. (Switzerland)
  
• Grifols, S.A. (Spain)
  
• Hologic, Inc. (USA)
  
• Immucor, Inc. (USA)
  
• Meridian Bioscience, Inc. (USA)
  
• Ortho Clinical Diagnostics (USA)
  
• Quotient Limited (UK)
  
• Siemens Healthineers AG (Germany)
  
• Sysmex Corporation (Japan)
  
• Thermo Fisher Scientific Inc. (USA)
  
• Danaher Corporation (USA)
  
• Grifols Diagnostic Solutions Inc. (USA)
  
• Haemonetics Corporation (USA)
  
• Luminex Corporation (USA)
  
• Natera, Inc. (USA)
  
• Novartis International AG (Switzerland)
  
• PerkinElmer, Inc. (USA)
  
• Promega Corporation (USA)
  

Long-Term Impact in the Next 10 Years a Shift Towards Personalized and Preventive Healthcare

Over the next decade, the blood screening market will continue to move toward highly personalized preventive healthcare. The integration of cutting-edge technologies such as CRISPR-based diagnostics and liquid biopsies will transform early diagnosis and testing for many conditions. Also, automation and AI-powered machines will become standard in hematology labs, increasing efficiency and reducing human error. In the long term, the market will play an important role in the global shift towards precision medicine, with blood tests becoming an integral part of routine health checks and disease prevention strategies.

In June 2024, Illumina Inc. successfully combined its latest product, XLEAP-SBS, with all reagents for its NextSeq 1000 and NextSeq 2000 next-generation sequencing (NGS) equipment.

In February 2024, Dyadic International Inc. together with Cygnus Technologies, a division of Maravai LifeSciences quantified the Host Cell Proteins (HCP) of C1-patented cells. Cygnus developed the C1 HCP ELISA Kit, which will be offered with Cygnus to both customers.

View report summary and Table of Contents (TOC) :

This report covers the following segments:

A. Product & Service